Page 59 - Read Online

Stenina-Adognravi et al. Vessel Plus 2018;2:30 I http://dx.doi.org/10.20517/2574-1209.2018.40 Page 9 of 14

Copyright
© The Author(s) 2018.

REFERENCES

1. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
2. Wang M, Zhao J, Zhang L, Wei F, Lian Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer 2017;8:761-73.
3. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, et al. The role of tumor-infiltrating immune cells and chronic inflamma-
tion at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol
2011;6:824-33.
4. Belli C, Trapani D, Viale G, D’Amico P, Duso BA, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev 2018;65:22-
32.
5. Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death
Dis 2018;9:115.
6. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and
recurrence. Nat Rev Cancer 2015;15:409-25.
7. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 2014;15:1243-53.
8. LaValley DJ, Zanotelli MR, Bordeleau F, Wang W, Schwager SC, et al. Matrix stiffness enhances VEGFR-2 internalization, signaling,
and proliferation in endothelial cells. Converg Sci Phys Oncol 2017;3:4.
9. Ng CF, Frieboes HB. Model of vascular desmoplastic multispecies tumor growth. J Theor Biol 2017;430:245-82.
10. Neve A, Cantatore FP, Maruotti N, Corrado A, Ribatti D. Extracellular matrix modulates angiogenesis in physiological and pathological
conditions. Biomed Res Int 2014; doi: 10.1155/2014/756078.
11. Yang L, Lin PC. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Semin
Cancer Biol 2017;47:185-95.
12. Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker
for breast cancer patients. BMC Cancer 2012;12:306.
13. Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, et al. Outcomes in patients with early-stage breast cancer who underwent a
21-gene expression assay. Cancer 2017;123:2422-31.
14. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb
Perspect Biol 2011; doi: 10.1101/cshperspect.a005058.
15. Adams JC, Lawler J. The thrombospondins. Cold Spring Harb Perspect Biol 2011; doi: 10.1101/cshperspect.a009712.
16. Tan K, Lawler J. The interaction of thrombospondins with extracellular matrix proteins. J Cell Commun Signal 2009;3:177-87.
17. Stenina-Adognravi O. Invoking the power of thrombospondins: regulation of thrombospondins expression. Matrix Biol 2014;37:69-82.
18. Hellewell AL, Gong X, Schärich K, Christofidou ED, Adams JC. Modulation of the extracellular matrix patterning of thrombospondins
by actin dynamics and thrombospondin oligomer state. Biosci Rep 2015; doi: 10.1042/BSR20140168.
19. Bentley AA, Adams JC. The evolution of thrombospondins and their ligand-binding activities. Mol Biol Evol 2010;27:2187-97.
20. McCart Reed AE, Song S, Kutasovic JR, Reid LE, Valle JM, et al. Thrombospondin-4 expression is activated during the stromal re-
sponse to invasive breast cancer. Virchows Arch 2013;463:535-45.
21. Posey KL, Hankenson K, Veerisetty AC, Bornstein P, Lawler J, et al. Skeletal abnormalities in mice lacking extracellular matrix pro-
teins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol 2008;172:1664-74.
22. Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, et al. Effects of THBS3, SPARC and SPP1 expression on biological
behavior and survival in patients with osteosarcoma. BMC Cancer 2006;6:237.
23. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin
Cancer Res 2011;17:1850-7.
24. D’Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, et al. Genome-wide expression profile of sporadic gastric cancers with micro-
satellite instability. Eur J Cancer 2009;45:461-9.
25. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell
2002;1:203-9.
26. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer pa-
tients treated with tamoxifen. Cancer Cell 2004;5:607-16.
27. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. The genomic and transcriptomic architecture of 2,000 breast tumours re-
veals novel subgroups. Nature 2012;486:346-52.
28. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, et al. Novel markers for differentiation of lobular and ductal invasive
breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007;7:55.
29. Förster S, Gretschel S, Jöns T, Yashiro M, Kemmner W. THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas,
identified by transcriptome-wide expression profiling. Mod Pathol 2011;24:1390-403.
30. Su F, Zhao J, Qin S, Wang R, Li Y, et al. Over-expression of thrombospondin 4 correlates with loss of miR-142 and contributes to mi-
gration and vascular invasion of advanced hepatocellular carcinoma. Oncotarget 2017;8:23277-88.
31. Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, et al. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro
and in vivo. Invest New Drugs 2009;27:304-18.